Lexeo Therapeutics (LXEO) Q2 2026 earnings summary

Executive summary

• LX2006 pivotal trial protocol finalized and initiated in June 2026 for Friedreich ataxia cardiomyopathy, with BLA submission targeted for H1 2028 under accelerated approval.

• LX2020 received RMAT designation in August 2026 for PKP2 arrhythmogenic cardiomyopathy, with ongoing Phase 1/2 trial showing dose-dependent efficacy and safety.

• Advanced clinical programs LX2006 and LX2020 showed positive interim data, with regulatory designations supporting expedited development.

• No product revenue yet; operations funded by equity offerings and warrant exercises.

• Strong cash position of $234.2M as of June 30, 2026, expected to fund operations into 2028.

Financial highlights

• Cash, cash equivalents, and investments totaled $234.2M as of June 30, 2026, with an additional $14.1M raised in July 2026.

• Net loss was $25.9M for Q2 2026 (vs. $26.1M Q2 2025) and $46.1M for H1 2026 (vs. $58.8M H1 2025).

• Operating expenses for Q2 2026: R&D $19.0M (+$4.3M YoY), G&A $9.0M (–$7.0M YoY).

• Interest income increased to $2.2M in Q2 2026 due to higher invested balances.

• Total assets were $246.6M and total liabilities $19.8M as of June 30, 2026.

Outlook and guidance

• Cash runway expected to fund operations into 2028.

• Topline data from the SUNRISE-FA 2 pivotal trial for LX2006 expected in H2 2027.

• 12-month data update for high dose LX2020 participants expected in Q4 2026.

• Anticipates continued net losses and increased R&D and G&A expenses as clinical programs advance and commercialization preparations begin.

• Focus remains on advancing pivotal and Phase 1/2 trials, expanding pipeline, and preparing for regulatory submissions.